MRK
Merck & Co., Inc.
Is MRK Halal?
Large-cap global pharmaceutical company developing and selling prescription medicines and vaccines — permissible pharmaceutical business.
What You Should Know
Merck & Co. (known as MSD outside the United States and Canada) develops prescription medicines, vaccines and animal-health products. Its March 31, 2026 Form 10-Q reports $128,685 million of assets, $49,117 million of debt, $5,327 million of cash, $476 million of debt securities, $12,210 million of receivables and $16,286 million of quarterly revenue. Debt/assets is 38.16%, so the examined FTSE Yasaar, MSCI and Malaysia asset-ratio screens fail; disclosed interest income is $35 million (0.21% of quarterly revenue). The healthcare mission is generally permissible, but product, licensing and customer allocation remains qualitative.
⚠️ Concerns
- •Debt/assets exceeds the examined 33% limits
- •Acquisition-related leverage
- •Animal-health product mix
- •Disclosed interest income and no universal activity numerator
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
49,117 / 128,685
5,803 / 128,685
17,537 / 128,685
35 / 16,286
- Financial
- Fails
- Overall
- Fails
Debt/assets is 38.16%, above the examined 33.333% limit; liquidity/assets is 4.51%, receivables-plus-cash/assets is 13.63% and disclosed interest income is 0.21%.
- Financial
- Fails
- Overall
- Fails
Debt/assets is 38.16%, above the examined 33.33% limit; liquidity and receivables-plus-cash remain below the examined limits.
- Financial
- Fails
- Overall
- Fails
Debt/assets is 38.16%, above the examined Malaysia 33% limit; liquidity/assets is 4.51%. This calculation is not an official classification.
- Financial
- Not calculated
- Overall
- Incomplete
A properly licensed and reproducible historical market-cap series is not stored; filing-based asset ratios remain documented.
Business-activity disclosure
Merck develops and sells prescription medicines, vaccines and animal-health products. The healthcare mission is generally permissible, while product formulation, licensing and customer allocation require qualitative review.
Limitation: The filing does not provide a universal prohibited-activity numerator across products, licenses and customers.
Purification
Merck discloses $35 million of interest income but does not provide a scholar-approved purification percentage or complete prohibited-activity numerator.
Inputs, assumptions and primary sources
- Amounts are USD millions from Merck's March 31, 2026 Form 10-Q.
- Interest-bearing debt is $2,444 million current debt plus $46,673 million noncurrent debt; operating-lease liabilities are not added because the latest balance-sheet lease split in the filing is from the prior year-end.
- Cash and cash equivalents are $5,327 million, available-for-sale debt securities are $476 million and accounts receivable are $12,210 million.
- Quarterly revenue is $16,286 million and disclosed interest income is $35 million, or 0.21% of quarterly revenue.
- Pharmaceuticals and animal-health products are generally permissible, but product, licensing and customer allocation are not reduced to a universal prohibited-revenue numerator.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →